Clinical Research Informer

Second unanimous FDA adcomm vote boosts bluebird bio

pharmaphorum

JUNE 12, 2022

Beti-cel has already been approved for marketing in Europe as Zynteglo, with a price tag of around $1.8 million price tag, saying its ability to help patients reach sustained transfusion independence justified its high price. Beti-cel offers another potentially curative treatment for a much broader range of patients.

Gene Therapy

Gene Therapy Gene Marketing Trials

ICER says bluebird bio’s $2.1m gene therapy is cost-effective

pharmaphorum

APRIL 14, 2022

million price tag. Patients with the most severe form of inherited disorder develop life-threatening anaemia from the age of around four to six months and have to undergo monthly blood transfusions as well as additional treatment to prevent complications, such as chelation drugs to remove excess iron from the body.

Gene Therapy

Gene Therapy Gene Marketing Clinical Trials

bluebird bio to split into oncology and gene therapy specialists

pharmaphorum

JANUARY 11, 2021

Late last year, bluebird’s shares tanked after the FDA laid out additional manufacturing standards for its lead gene therapy product, Lentiglobin, in sickle cell anaemia that could hold up filing until late 2022. million price tag.

Gene Therapy

Gene Therapy Gene Genetic Disease Manufacturing

Second unanimous FDA adcomm vote boosts bluebird bio

ICER says bluebird bio’s $2.1m gene therapy is cost-effective

bluebird bio to split into oncology and gene therapy specialists

Stay Connected